Short answer
Dexcom (DXCM) filed its Q2 2026 10-Q quarterly report on Jul 30, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $1.3B (up 13.1% year over year) with net income of $249M.
Q2 2026 key financials · XBRL
- Revenue
- $1.3B
- +13.1% YoY · +9.8% QoQ
- Net income
- $249M
- +38.5% YoY · +24.9% QoQ
- Operating margin
- 24.3%
- Gross margin
- 63.4%
- EPS (diluted)
- $0.64
- +45.5% YoY · +25.5% QoQ
Source: XBRL data from the Dexcom (DXCM) Q2 2026 10-Q on SEC EDGAR. USD.
Dexcom Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No profitability, margin, cash-flow, or capital-deployment figures provided
- Forward-looking statements subject to risks and uncertainties affecting future performance
- Management assumes no obligation to update forward-looking statements
Risk Factors
- No specific new, changed, regulatory, operational, competitive, or financial risk identified in the provided excerpt
- General uncertainty risk: unidentified or currently immaterial risks could materially harm business, financial condition, or results
- Equity-holder risk: adverse risk developments could reduce common-stock value and cause partial or total investment loss
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Dexcom quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.